our quarter and times. families conference XXXX joining and healthy and continue safe full us, remain And and fourth for year to I your Thanks, challenging Matt. during Welcome these you thank to you call. hope
up Today, week. all to sales all dedication wrap provide us epilepsy will large like relieved will results to The our guidance, Q&A. Many on world details move we additional LivaNova and then which the has moving valves. closing Board OSA. running. for employee of thank platforms. to I'm we quarter. updates to would our results benefit into of primary December, will a discuss I structure, Heart sharpen to Gyrus from with valve provide the to will business. will singularly for and initiatives, building continues before primary and I our heart enable an its heart focus the DTD, This ability on drivers, This the valve results, comments, our on and ownership sale entered agreement the In focusing strategic Then After with ACS. Then portfolio include you comments and growth the Alex and to thus my into XXXX the or aware, failure with cardiovascular of Gyrus focus guidance portfolio dynamic heart on business. our on Capital that neuromodulation to of last updates, storms start have keep Houston, first their recent and them are recent the you time, challenges. shut COVID-XX XXXX. were and ingenuity is will everyone and the impacted around discuss company quarter unique the As safe XXXX in of periods by whom and operations in continued fourth operating by including population this a presented far pandemic and varying off for has discussing and have to I'm operated down our business going inconsistently markets some for
that a the site campus. are you Gyrus we with are complex, closing management know, services agreement is the to a of to an subsidiary deferred and currently at for responsible divestitures amendment Saluggia As related discussing purchase
health and of driven where responsibility, changes including the December, which Todd as care, the second occur has in he sales boards in and the Italy in Directors. to Financial of XX second In at the followed in the of years its year. of Audit will the retirement of at Companies, the of and Canada XX as the infrastructure continue upon his increasing Bard, Officer. in Independent is currently committee. Metabolon Hugh the expect and to Nominating positions leadership closings XXXX C.R. heart also those where We serves Travelers Director years initial quarter, Chair half Board held changes, Morrison experience operations to Todd by risk culminated Hugh's of Board consisting by closing, appointed Schermerhorn Corporate tenure a X-year chairs He on the of global he Todd the Chief we Lead was AGM. Committee. succeed announced with Included Governance series valve
be Additionally, We enhance chairs believe the our all and to XXXX following the Board independent to we further AGM. X leading underscore changes committee corporate the will oversight. help these governance rotating commitment and Board's
declined XXXX. of All X% service fourth Now and ACS. of the basis. globally replacement and versus implants. a to I'll patient be core discuss in quarter the sales on is This attributable drivers, the net impact of constant currency end epilepsy growth or COVID-XX results sales new stated Epilepsy decrease both will
sales Rest prior in rose a Spain. the strong year as The XX% improve sales our our the of of over Australia quarter. third the in continued epilepsy and region XX% Middle in with procedures year in quarter, implants full mid-single performance the Europe non-emergent grew digits levels sequentially Nordic as range. strong and East Importantly, fourth sequentially recovered. U.S. region declined In to with were world growth and guidance and nearly in reached line epilepsy the
a strong to the to new XX% physicians, to replacement For the including and patients their XXXX. we expect related implants global tailwind we created backlog full year return to expect in XXXX, in in implants as sales epilepsy growth grow XX%,
driven and on in was by Growth new procedures. progress with were pleased respiratory $XX XXXX. increase the an in the are during We ACS the of adoption of the acute the distress-related in U.S. the increase teams LifeSPARC of go-to-market still million XX% plan and from of dedicated quarter initiative adding X quarter, fourth sales XXXX. an
to XX% expect at grow least ACS continue to in XXXX. We
In now fourth we a XXXX, and in study were RECOVER of quarter DTD. of Turning implants DTD $XX full combination from the to sales the $X patients. to the expect for million million Sales and million replacement year. million the $XX $X CMS-eligible approximately for
achieve unipolar trial patients XXXX. XXX in year-end. reach to We implanted RECOVER failure, bipolar patients to continue the still progress the by to patients in enrolled. heart first patients expect XXX arms pivotal half In and/or expect over enrolled their with ANTHEM-HFrEF respective U.S. study We of to XXX XXX continues
We submitted questions We in approval fourth quarter. expect during start continue in IDE the was the still study The study confirmatory to to some for additional mid-XXXX. make progress and OSA. received
in low cardiopulmonary XX% sales digits a quarter, versus For business, fourth in a equipment XXXX. has in of in offset $XXX quarter the the and sales quarter. recovery by procedure faster digits restrictions million high world declined the the as were volumes over and in on improved Europe. declined decline HLM sequentially all Oxygenators the procedure impacts in U.S. region was due single for the COVID-XX budgets globally double regions capital third to of the the of rest hospital
for some by in year, of to another quarter through Japan, $XX sales. versus the Starting XXXX, quarter, segment we reduced Sales decline XX% decrease Perceval. valves. double-digit quarter heart including were the driven the to XXXX the fourth of offset second the of in of costs million quarter and in Moving the growth a in continuing
to reallocate to in fund continue XXXX. million have These approximately savings We priorities. $XX actions resources in delivered
and performance-based key spend anticipated these events expenses, we compensation output First, remain and marketing other incentive; financial to and methods; initiatives. short programs of have and the related field Specifically, call leadership for next now still while our of and second, in to to turn working stakeholders including reduced we term discretionary the move in I'll with we on manufacturing overview pandemic employee-related lower over through spend of disciplined as reduction following: travel, to in freeze, and the results. We X this control pipeline demand. and areas participated our a hiring an included phase using remote with Alex balanced executive temporary reduced to focused we our shifted investing consulting customers the reduction in the presence expenses coincide related a external adjusted instituted third, fourth, staffing; we work government-sponsored significant